

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 38931

Manuscript Type: REVIEW

Anti-integrin therapy for inflammatory bowel disease

Sung Chul Park, Yoon Tae Jeen

Abstract

In inflammatory bowel disease (IBD), tumor necrosis factor plays an important role in mediating inflammation, but several other pathways are also involved in eliciting an inflammatory response. One such pathway is the invasion of the intestinal mucosa by leukocytes. Leukocytes within the systemic circulation move to sites of inflammation, and blocking this pathway could be an important treatment strategy for IBD. Anti-integrin therapy blocks the action of integrin on the surface of

Match Overview

1	Crossref 165 words Sung Chul Park, Yoon Tae Jeen. "Current and Emerging Biologics for Ulcerative Colitis", <i>Gut and Liver</i> , 2015	2%
2	Internet 64 words crawled on 12-Dec-2017 orbi.ulg.ac.be	1%
3	Internet 57 words crawled on 04-Jul-2017 www.nice.org.uk	1%
4	Publications 51 words "Studies from University of Washington Update Current Data on Antisense Technology [Antisense therapy]", <i>Hear</i>	1%
5	Crossref 42 words Lam, Mindy CW, and Brian Bressler. "Vedolizumab for ulcerative colitis and Crohn's disease: results and implications"	<1%
6	Internet 40 words crawled on 03-Apr-2018 www.nature.com	<1%



全部

图片

新闻

视频

购物

更多

设置

工具

找到约 394,000 条结果 (用时 0.41 秒)

Google 学术: Anti-integrin therapy for inflammatory bowel disease

... in development for inflammatory bowel diseases - Soler - 被引用次数: 182

... after natalizumab therapy for Crohn's disease - Van Assche - 被引用次数: 1020

... of disease: pathogenesis of Crohn's disease and ... - Sartor - 被引用次数: 1384

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780165/> ▼ 翻译此页

作者: H Singh - 2016 - 被引用次数: 10 - 相关文章

跳到PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE: ROLE OF ... - IBD occurs due to infiltration of leukocytes in intestinal mucosa and derangements in intestinal barrier function. One of the most important steps in pathogenesis of IBD is the interactions between **integrins** on the surface of leukocyte and their ...

INTRODUCTION · CURRENT TREATMENT ... · CLINICAL PHARMACOLOGY

Efficacy and safety of antiintegrin antibody for inflammatory bowel ...

<https://www.ncbi.nlm.nih.gov/pubmed/25761174> ▼ 翻译此页

作者: L Lin - 2015 - 被引用次数: 18 - 相关文章

Efficacy and safety of **antiintegrin** antibody for **inflammatory bowel disease**: a systematic review and meta-analysis. ... an epitope comprising the $\alpha 4\beta 7$ heterodimer; natalizumab, which recognizes the $\alpha 4$ integrin subunit; etrolizumab, which is specific for the $\beta 7$ subunit—in the **treatment** of CD and ulcerative



全部 图片 新闻 视频 购物 更多

设置 工具

找到约 253,000 条结果 (用时 0.51 秒)

Google 学术 : Anti-integrin therapy for inflammatory bowel disease

... in development for inflammatory bowel diseases - Soler - 被引用次数 : 186

... after natalizumab therapy for Crohn's disease - Van Assche - 被引用次数 : 1029

... of disease: pathogenesis of Crohn's disease and ... - Sartor - 被引用次数 : 1395

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780165/> - 翻译此页

作者 : H Singh - 2016 - 被引用次数 : 10 - 相关文章

跳到PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE: ROLE OF ... - IBD occurs due to infiltration of leukocytes in intestinal mucosa and derangements in intestinal barrier function. One of the most important steps in pathogenesis of IBD is the interactions between integrins on the surface of leukocyte and their ...

INTRODUCTION · CURRENT TREATMENT ... · CLINICAL PHARMACOLOGY

Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532375/> - 翻译此页

作者 : S Zundler - 2017 - 被引用次数 : 5 - 相关文章

2017年7月28日 - Finally, we will comment on noteworthy clinical aspects of anti-adhesion therapy and give an outlook to the future of anti-integrin antibodies and inhibitors. Keywords: inflammatory bowel diseases, ulcerative colitis, Crohn's disease, vedolizumab, natalizumab, etrolizumab, gut homing, integrins. Go to: ...

Abstract · Introduction · Molecular Aspects of Anti ... · Clinical Aspects of Anti ...

找到约 336,000 条结果 (用时 0.39 秒)

Google 学术: Anti-integrin therapy for inflammatory bowel disease

... in development for inflammatory bowel diseases - Soler - 被引用次数: 185

... after natalizumab therapy for Crohn's disease - Van Assche - 被引用次数: 1031

... of disease: pathogenesis of Crohn's disease and ... - Sartor - 被引用次数: 1399

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780165/> - 翻译此页

作者: H Singh - 2016 - 被引用次数: 10 - 相关文章

跳到PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE: ROLE OF ... - IBD occurs due to infiltration of leukocytes in intestinal mucosa and derangements in intestinal barrier function. One of the most important steps in pathogenesis of IBD is the interactions between integrins on the surface of leukocyte and their ...

INTRODUCTION - CURRENT TREATMENT ... - CLINICAL PHARMACOLOGY

Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532375/> - 翻译此页

作者: S Zundler - 2017 - 被引用次数: 5 - 相关文章

2017年7月28日 - Finally, we will comment on noteworthy clinical aspects of anti-adhesion therapy and give an outlook to the future of anti-integrin antibodies and inhibitors. Keywords: inflammatory bowel diseases, ulcerative colitis, Crohn's disease, vedolizumab, natalizumab, etrolizumab, gut homing, integrins. Go to: ...

Abstract - Introduction - Molecular Aspects of Anti ... - Clinical Aspects of Anti ...

Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular ...

<https://www.ncbi.nlm.nih.gov/pubmed/28804488> - 翻译此页

作者: S Zundler - 2017 - 被引用次数: 5 - 相关文章

2017年7月28日 - Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects. Zundler S(1) ... Anti-adhesion antibodies selectively target integrins controlling cell homing to the intestine, which leads to reduction of inflammatory infiltration to the gut in chronic intestinal inflammation. Currently, the ...